Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Mimetogen: An eye for neuroprotection

Mimetogen Pharmaceuticals Inc. believes it is the first company attempting to treat glaucoma and other degenerative ophthalmic diseases through neuroprotection, an approach it expects would complement existing drugs.

The company's lead compound mimics the pro-survival effects that nerve growth factor (NGF) has on retinal cells. A second program targets a neurotoxic protein that is up-regulated in response to high intraocular pressure and is

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers